Glicentin ELISA

(10-1273-01)

Kit format: 1 x 96 wells

Measurement range: 3 – 300 pmol/L (24 – 2400 pg/mL)

Highly specific, sensitive and rapid method for determination of glicentin

No cross-reactivity to circulating proglucagon derived gut peptides

Assay buffers and calibrators have been optimized to prevent degradation and aggregation of glicentin

TALK TO A PERSON

Description

The Mercodia Glicentin ELISA is a high-quality immunoassay for the quantification of human glicentin in serum, plasma, and cell culture media.

Glicentin is a proglucagon-derived gut peptide that is released in the gut in response to feed intake. It is present in high levels in the circulation after stimulation and is often a problem when measuring glucagon and other proglucagon derivates because of its shared sequence. The Mercodia Glicentin ELISA however, has no cross-reactivity to such circulating proglucagon-derived gut peptides.

Want to read more about our Glicentin ELISA and other Mercodia ELISAs, see this White Paper.

Test characteristics

Species

Human

Sample types

Serum, EDTA plasma and cell culture media

Sample volume

25 µL

Assay range

3 - 300 pmol/L (24-2400 pg/mL)

Detection limit

≤3 pmol/L (24 pg/mL)

Incubation

1 h + 1 h + 15 min

Detection method

Absorbance

specificity

The following cross-reactions have been tested:

Glucagon

Not detected

Oxyntomodulin

Not detected

Mini-glucagon

Not detected

GLP-1

Not detected

GLP-2

Not detected

Rat glicentin

0.9 %

Mouse glicentin

Not detected

directions for use Certificate of Analysis Safety Data Sheet

directions for use

LOT. NO.	DOCUMENT
35899	DfU - 10-1273-01 v. 5.0

Certificate of Analysis

LOT. NO.	DOCUMENT
35899	CoA - 10-1273-01

Safety Data Sheet

DOCUMENT
SDS - 10-1273-01

For other languages and previous versions: Technical Library

references

Manell, H. et al. (2016) Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents With Obesity and Type 2 Diabetes. J Clin Endocrinol Metab 101, 1181–1189. Read more >

Raffort, J. et al. (2017) Fasting Circulating Glicentin Increases After Bariatric Surgery.Obes. Surg. 27, 1581–1588. Read more >

Poitou, C. et al. (2018) Fasting levels of glicentin are higher in Roux-en-Y gastric bypass patients exhibiting postprandial hypoglycemia during a meal test. Surg. Obes.Relat. Dis. 14, 929–935. Read more >

Roberts, G. P. et al. (2018) Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery. Surg. Obes. Relat. Dis. 14, 562–568. Read more >